GRAIL, Inc.
Financials
Valuation Metrics
GRAIL, Inc.'s Market Cap is $3.61B. At end of 2025 it was $3.49B. Ranked #1603 of 3,121 in US market (top 51%), #566 of 1,463 on NASDAQ (top 39%), #98 of 205 in Health Care Equipment & Services (top 48%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.61B | US#1,603/3,121 Sec#98/205 |
| Revenue | $165M | US#2,616/3,121 Sec#172/205 |
| Net Income | $-392M | US—/3,121 Sec—/205 |
| Total Assets | $2.84B | US#1,856/3,121 Sec#90/205 |
| Net Assets | $2.54B | US#1,083/3,121 Sec#57/205 |
| Employees | 910 | US#2,027/3,121 Sec#140/205 |
| Value | ||
| P/B | 1.42x | US#788/3,121 Sec#39/205 |
| P/S | 21.83x | US#2,854/3,121 Sec#199/205 |
| FCF Yield | -8.18% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -15.40% | US#2,433/3,121 Sec#143/205 |
| ROA | -13.77% | US#2,726/3,121 Sec#163/205 |
| Op. Margin | -338.40% | US#2,795/3,121 Sec#197/205 |
| Revenue Growth | 23.07% | US#592/3,121 Sec#38/205 |
| Financial Health | ||
| Debt Ratio | 11.84% | US#133/3,121 Sec#7/205 |
| Total Debt | $91M | US#2,468/3,121 Sec#141/205 |
| FCF | $-295M | US#2,844/3,121 Sec#202/205 |
| Cash | $56M | US#2,545/3,121 Sec#161/205 |
| Current Ratio | 10.95x | US#231/3,121 Sec#7/205 |
| Performance | ||
| 1Y Return | 104.02% | US#192/3,121 Sec#21/205 |
| 1M Return | 9.21% | US#180/3,121 Sec#26/205 |
| From 52W High | -32.03% | US#2,197/3,121 Sec#146/205 |
| 1Y MDD | -62.92% | US#2,840/3,121 Sec#179/205 |
| Trading | ||
| Volume | 2,770,616 shares | US#1,044/3,121 Sec#62/205 |
| Trading Value | $223M | US#715/3,121 Sec#63/205 |
| Per Share | ||
| EPS | $-8.77 | US—/3,121 Sec—/205 |
| BPS | $56.93 | US#360/3,121 Sec#31/205 |
Company Info
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.